Inside BENEO’s new pulse plant: pioneering sustainable protein from faba beans
Acquisition to strengthen Eris’ metabolic and women’s health segments
Eris Lifesciences announced the acquisition of the prescription probiotics business of Velbiom Probiotics (Velbiom) for a consideration of Rs 50 crore. The strategic move strengthens Eris’ franchises in Metabolic Wellness and Women’s Healthcare. Velbiom is a science-driven bio-therapeutics company committed to the advancement of India-specific microbiome based therapy and research. It is India’s first exclusive probiotic company with a wide range of disease specific, strain specific and site-specific probiotic formulations.
Key brands acquired as part of the deal:
Lactogut — Multi-strain gastrointestinal health formulation
Lactogut UG —Recurrent UTI/ Urogenital Wellness in Women
Lactovit — Daily gut wellness and immune support
Amit Bakshi, CMD, Eris Lifesciences said, “Prebiotics/ Probiotics represent a fast-growing and high-potential adjacency to our core diabetes and cardio-metabolic franchises. The clinical synergies between GLP-1 therapies and gut microbiome health create a compelling opportunity for Eris to differentiate its disease management proposition.”